National Bank of Canada
ABUS icon

National Bank of Canada’s Arbutus Biopharma ABUS Stock Holding History

National Bank of Canada’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.14K Buy
700
+41
+6% +$179 ﹤0.01% 2546
2025
Q4 		$3.17K Sell
659
-41
-6% -$184 ﹤0.01% 2511
2025
Q3 		$3.18K Hold
700
– – ﹤0.01% 2529
2025
Q2 		$2.16K Hold
700
– – ﹤0.01% 2613
2025
Q1 		$2.44K Sell
700
-907
-56% -$3.02K ﹤0.01% 2479
2024
Q4 		$5.25K Sell
1,607
-97
-6% -$357 ﹤0.01% 2440
2024
Q3 		$6.56K Sell
1,704
-1,006
-37% -$3.86K ﹤0.01% 2160
2024
Q2 		$8.43K Buy
2,710
+1,000
+58% +$3K ﹤0.01% 2161
2024
Q1 		$4.92K Sell
1,710
-110
-6% -$285 ﹤0.01% 2309
2023
Q4 		$4.69K Hold
1,820
– – ﹤0.01% 2321
2023
Q3 		$3.45K Sell
1,820
-300
-14% -$629 ﹤0.01% 2427
2023
Q2 		$4.87K Hold
2,120
– – ﹤0.01% 2348
2023
Q1 		$6.41K Hold
2,120
– – ﹤0.01% 2241
2022
Q4 		$4.92K Buy
2,120
+300
+16% +$718 ﹤0.01% 2338
2022
Q3 		$3K Hold
1,820
– – ﹤0.01% 2420
2022
Q2 		$5K Hold
1,820
– – ﹤0.01% 2409
2022
Q1 		$5K Hold
1,820
– – ﹤0.01% 2531
2021
Q4 		$7K Buy
+1,820
New +$7.07K ﹤0.01% 2449

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

National Bank of Canada's ABUS Position: Q1 2026 in Review

National Bank of Canada increased its Arbutus Biopharma (ABUS) stake by 6.2% in Q1 2026, buying an estimated $179 and bringing the position to 700 shares worth $3.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

National Bank of Canada first reported a position in ABUS in Q4 2021 and has held it in 18 quarters since. The position peaked at $8.43K in Q2 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • National Bank of Canada held 700 shares of Arbutus Biopharma worth $3.14K as of Q1 2026.
  • National Bank of Canada bought 41 Arbutus Biopharma shares in Q1 2026, an estimated $179.
  • Arbutus Biopharma made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2546 holding.
  • National Bank of Canada first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 18 quarters since.
  • National Bank of Canada's Arbutus Biopharma position peaked at $8.43K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.